In
HIV and ID Observations, Dr. Paul Sax provides an update on interferon lambda for COVID-19, which hasn't been approved by the FDA.
Peginterferon lambda was tied to fewer hospitalizations and emergency department visits among COVID-19 outpatients in a recent study. In the latest HIV and ID Observations, Dr. Paul Sax takes a closer look at this novel therapy — and hopes it gets another chance.
Do you want to be notified whenever Dr. Sax posts? Sign up to receive notifications by email by using the Subscribe box.
Want to see more from NEJM Journal Watch? Register here.